Other News To Note
• Sigma-Tau Pharmaceuticals Inc., of Gaithersburg, Md., said the FDA approved Cystaran (cysteamine ophthalmic solution) 0.44 percent, a topical ophthalmic therapeutic developed in partnership with the National Institutes of Health, for the treatment of corneal cysteine crystal accumulation as a result of cystinosis. Cystaran is designated an orphan drug in the U.S.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter